Role of LH administration during the follicullar phase in women with risk of low response in ovarian stimulation with FSH and cetrorelix for IVF;Papel de la administración de LH en el curso de la fase folicular en mujeres con riesgo de pobre respuesta en ciclos de estimulación con FSH y cetrorelix para FIV

Revista Iberoamericana de Fertilidad y Reproduccion Humana

Volumn 23, Issue 5, 2006, Pages 281-290

  Fernandez Ramirez M J ^b   Monzo A ^a   Garcia Gimeno T ^a   Rubio, J M ^a   Montanana V ^a   Duque, C ^a   Herrero, G ^a   Romeu, D Alberto ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL MARINA BAIXA   (Spain)

Author keywords

GnRH antagonists; ICSI; In vitro fertilization (IVF); Low response; Recombinant FSH; Recombinant LH

Indexed keywords

CETRORELIX; ESTRADIOL; FOLLITROPIN; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; FERTILIZATION; FERTILIZATION IN VITRO; FOLLICULAR PHASE; FOLLITROPIN BLOOD LEVEL; HORMONE INHIBITION; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LUTEINIZING HORMONE BLOOD LEVEL; METAPHASE; OOCYTE DEVELOPMENT; OOCYTE DONATION; OVARY FOLLICLE DEVELOPMENT; OVULATION INDUCTION; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 34247230197     PISSN: 11320249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Scott RT Jr. MD.: Evaluation and treatment of low responders. Seminars in Reproductive Endocrinology, 1996; 14, 317-337.
2. Pellicer A, Ballester MJ, Serrano MD, et al.: Aetiologic factors envolved in the low response to gonadotropins in infertile women with normal basal serum follicle stimulating hormone. Hum Reprod, 1994; 9:806-11.
3. Ben-Rafael, Z, et al.: Limitations in the use of combined gonadotropin-releasing hormona analog and human menopausal gonadotropin for in in vitro fertilization, in Advances in assisted reproductive technologies, S. Mashiach, et al., Editors. 1990, Plenum Press: New York. P 17
4. Scott, RJ.: Evaluation and treatment of low responders. Semin Reprod Endocrinol, 1996. 14: 317-337.
5. Faber B, et al.: Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favourable pregnancy results in low responders. Fertil Steril, 1998; 69: 826-830.
6. Barri, P, et al.: Managing nonresponders, in Fertility and Reproductive medicine, R. Kempers, et al, Editors. 1998, Elsevier Science BV: Amsterdam. 127-137
7. BancsiLF BF, Bijkemans MJ, de Jong FH, Habbema JD, te Velde ER.: Predictors of poor ovarian response in invitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril 2002; 77 328-36
8. Evers J, Slaats P, Land JA, Dumoulin JC, Dunselman GA.: Elevated levels of basal estradiol-17beta predict poor response in patients with normal basal levels of follicle-stimulating hormone undergoing in vitro fertilization. Fertil Stenl 1998; 69 (6): 1010-4.
9. Seifer D, Lambert-Masserlian B, Hogan JW, Gariner AC, Blazar AS.: Day 3 serun inhibin-B is predictive of assisted reproductive thecnologies outcome. Fertile Steril 1997; 67: 110-14.
10. Fawzy M LA, Harrison RF, Knight PG, Groome N, Hennelly B, Robertson WR.: Day 5 inhibin-B levels in a treatment cycle are predictive of IVF outcome. Human Reprod 2002; 17 (6): 1535-43.
11. Wheatcroft NJ, Rogers CA, Metcalfe RA, et al.: Is subclinical ovarian failure an autoimmune disease? Human Reprod 1997; 12:244-9.
12. Matt DW, Kauma SW, Pincus SM, et al.: Characteristics of luteinizing hormone secretion in younger versus older premenopausal women. Am J Obstet Gynecol 1998; 178: 504-510.
13. Pellicer A, Marí M, De los Santos MJ, et al.: Effects of aging on the human ovary: the secretion of inmunoreactive alfa-inhibin and progesterone. Fertil Steril 1994; 61:663-8.
14. Cano F, Simón C, Remohí J, et al.: Effect of aging on the female reproductive system: evidence for the role of uterine senescente in the decline in female fecundity. Fertil Steril, 1995; 64: 584-89.
15. Remohí J, Gartner B, Gallardo E, et al.: Pregnancy and bith rates after oocyte donation. Fertil Steril 1997; 67:717-723.
16. Cameron, I, et al.: Occult ovarian failure: a syndrome of infertility, regular menses and elevated follicle stimulating hormone concentrations. J Clin Endocrin Metab, 1988; 67:1190-4.
17. Van Wely M, Westergaard L, Bossuyt P, Van der Veen F.: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. 2003.
18. Olivennes F, Mannaerts B, Struijs M, Bonduelle M, Devroey P.: Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report. Hum Reprod. 2001; 16:1588-91.
19. Acevedo B, Sánchez M, Gómez JL, Cuadros J, Ricciarelli E, Hernández ER.: Luteinizing hormona supplementation increases pregnancy rates in gonadotropin-releasing hormona antagonistdonor cycles. Fertil Steril 2004; 82:343-7.
20. Surrey E, Schoolcraft B.: Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril. 2000;73:667-76.
21. Weil S, Vendola K, Zhou J, Bondy CA.: Androgen and follice-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 1999;84 (8): 2951-6.
22. Romeu, M.: El fallo ovárico oculto y su importancia en reproducción asistida, Pediatría, Obstetricia y Ginecología. 2000: p 134.
23. Engel JB, Griesinger G, Schultze-Mosgau A, Felberbaum R, Diedrich K.: GnRH gonists an antagonists in assisted reproduction: pregnancy rate. Reprod Biomed Online. 2006 Jul;13(1): 84-7.
24. De Placido et al.: Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response. Fertil Steril. 2006; 85: 247-250.
25. Marin M, Rubio JM, Sánchez M, Urgal A, Monzó A, Romeu A.: Tratamiento de pacientes con pronóstico de baja respuesta: comparación de dos protocolos de supresión hipofisaria. Revista Iberoamericana de fertilidad.2005; 22: 123-130.
26. Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, et al.: Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Human Reprod; 19:1979-84 [Epub 2004 Jun 10].
27. Chung et al.: Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists. Fertil Steril 2005; 84:313-8.